First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Recent trends indicate a growing preference for actively managed funds as investors seek to navigate volatile markets, positioning JSMVX favorably for increased inflows.
What’s Driving the Stock
1The fund's recent shift to increase exposure in technology and healthcare sectors, which have shown 20%+ growth rates, could significantly enhance AUM growth.
2Recent investor sentiment surveys indicate a 15% increase in demand for actively managed funds, which could lead to increased inflows into JSMVX.
3The fund's historical outperformance against its benchmark by an average of 300 basis points over the last three years could attract more institutional investors.
4Increased volatility in the equity markets may lead to a flight to quality, benefiting funds with a strong performance history like JSMVX.
5Increased demand for active management in volatile markets
6Growth potential in technology and healthcare sectors
7Changes in AUM driven by market performance and investor sentiment
"Investors are increasingly looking for active management to outperform in uncertain times."
Moat: The fund's competitive advantage lies in its experienced management team and a proven investment strategy focused on high-growth potential.
growth - The fund appeals to investors seeking capital appreciation through exposure to high-growth small and mid-cap companies.
Rising interest rates can impact the cost of capital for the companies in which the fund invests, potentially slowing growth.
Watch on earnings: AUM growth rate, Net inflows/outflows, Performance relative to benchmark indices.
One Sentence Summary:
Jackson Square SMID-Cap Growth Fund: the setup is constructive — the fund's recent shift to increase exposure in technology and healthcare sectors, which have shown 20%+ growth rates.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.